D iabetic cardiomyopathy was initially described as a human pathophysiological condition in which heart failure occurred in the absence of coronary artery disease, hypertension, and valvular heart disease. Recent studies in diabetic animal models identify decreased cardiomyocyte function as an important mediating mechanism for heart failure. Decreased cardiomyocyte function is in part mediated by abnormal mitochondrial calcium handling and a decreased free matrix calcium level which could be a good target for new therapeutic interventions.
D iabetic cardiomyopathy was initially described as a human pathophysiological condition in which heart failure occurred in the absence of coronary artery disease, hypertension, and valvular heart disease. Recent studies in diabetic animal models identify decreased cardiomyocyte function as an important mediating mechanism for heart failure. Decreased cardiomyocyte function is in part mediated by abnormal mitochondrial calcium handling and a decreased free matrix calcium level which could be a good target for new therapeutic interventions.
Diabetic cardiomyopathy (DC) is a diabetes mellitus (DM)-induced pathophysiological condition that can result in heart failure (HF). Here, we present the point of view that diminished cardiomyocyte contraction is a significant contributor which is currently not included among the contributing mechanisms for DC and is largely mediated by changes in either the level or post-translational modification of specific cardiomyocyte proteins, or both. Correcting these changes may lead to novel therapeutic approaches.
HF, DM, and Cardiovascular Disease
DM occurs in 9.3% of the US population. The prevalence of HF is high in patients with DM, ranging from 19% to 26%. 1 HF occurs in both type 1 DM (T1D) and type 2 DM (T2D). T2D accounts for 90% to 95% of DM cases and is frequently linked to obesity.
In patients with DM, cardiovascular disease is the leading cause of death with coronary artery disease and ischemic cardiomyopathy as main contributors. In addition to coronary artery disease, small vessel disease and diminished cardiac capillary density occurs. Patients with DM can present initially with normal systolic contraction, but impaired diastolic cardiac function, 1 a condition termed HF with preserved ejection fraction (HFpEF) which may account for 50% of all HF.
In 1972, Rubler et al 2 identified a new type of cardiomyopathy in patients with DM termed DC. These patients had a history of HF in the absence of coronary artery disease, hypertension, or valvular heart disease, and it was postulated that the myocardial disease is due to diffuse myocardial fibrosis, cardiac hypertrophy, and diabetic microangiopathy. This definition does not include abnormal cardiomyocyte function and fits the data available at that time. The role of DM in HF was found in the Framingham study. 3 Human DC has become a well-documented condition. In T1D and T2D experimental animal models, decreased diastolic and systolic contractile function accompanied by diminished cardiomyocyte contraction and changes in specific cardiomyocyte proteins have been demonstrated. 4, 5 This leads to the point of view that abnormal contractile function of the diabetic cardiomyocyte could be included in the definition of DC to make it more integrated and conclusive.
In contrast to earlier trials, 6 more recent trials in patients with DM using sodium/glucose exchange inhibitors and glucagon-like peptide receptor agonists show significant improvements in cardiac contractile function. 1 In addition, if myocardial infarct area is adjusted to equal size in patients without DM and patients with DM, the incidence of HF is significantly higher in patients with DM than in those without the disease. These findings also suggest that ischemic and DC are frequently interrelated entities amplifying maladaptive contractile effects in patients with DM.
Mechanisms Contributing to the Development of DC
Multiple mechanisms contribute to decreased performance of the diabetic heart and have been reviewed. 1 They include exposure of the heart to the diabetic milieu of hyperglycemia along with increased fatty acids (FA) and cytokines. Hyperglycemia enhances enzymatic O-GlcNAcylation of cardiomyocyte proteins and is maladaptive. Increased chemical nonenzymatic AGE (advanced glycation end-product) formation also occurs with detrimental effects. A diabetic autonomic neuropathy is present and linked to hyperglycemia. Exposure to increased lipid levels including FA and triglycerides causes increased fat droplet accumulation in cardiomyocytes mediating cardiac lipotoxicity. Decreased insulin signaling is a hallmark of T1D and T2D, and alterations in other signaling cascades occur, including decreased AMPK (AMP-activated protein kinase) signaling and increased PKC (protein kinase C) and MAPK (mitogen-activated protein kinase) signaling with maladaptive consequences.
DM-Induced Changes in Specific Cardiomyocyte
Proteins Linked to Calcium (Ca
2+ ) Handling
Exploring DM-induced changes in molecular mechanisms mediating cytosolic and mitochondrial Ca 2+ handling may identify novel therapeutic approaches.
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Cytosolic Ca 2+ Handling in Diabetic Cardiomyocytes
In a T1D rat model, depressed sarcoplasmic reticulum function was reported by Penpargkul et al 4 The T2D model of Otsuka Long Evans Tokushima Fatty rats have reduced SERCA2a protein levels and exhibit impaired diastolic function. Treatment with adenoviral vectorbased SERCA2a transgene expression improves contractile function. Increased cardiomyocyte size in T2D hearts is restored to normal, but no influence on collagen production occurs. Although the exact mechanism(s) for these effects are uncertain, increased SERCA2a levels in isolated cardiomyocytes has been shown to increase the expression of genes linked to insulin signaling. 8 For human DC, only limited results for myocardial contractile function or the level of cardiomyocyte proteins are available. Actomyosin cross-bridge kinetics and work output at varying calcium concentrations were determined in male and female patients with DM. The findings suggest that changes in diabetic cardiac muscle function contribute to the incidence and mortality of DM-induced HF. 
Conclusion for DM and Cytosolic Ca

2+
Handling
The data from T1D and T2D animals justify the inclusion of abnormal cytosolic Ca 2+ handling in cardiomyocytes as an important contributor to DC. Studies in specific T1D and T2D animal models imply that different proteins linked to Ca 2+ handling are potential targets. Data from T1D mice and T2D rats point to SERCA2a, whereas results from T2D db/db mice also identify proteins linked to sarcoplasmic reticulum Ca 2+ release by the ryanodine receptor and its regulatory proteins.
Although quantitation of proteins linked to cytosolic Ca 2+ handling in human diabetic hearts is not available, patients with HF owing to other causes exhibit decreased SERCA2a expression and diminished contractile function. Based on findings in animals, restoring cytosolic Ca 2+ handling in human diabetic cardiomyocytes may be a promising strategy. Discussing the CUPID trials (Calcium Upregulation by Percutaneous Administration of Gene Therapy in Patients With Cardiac Disease), using AAV1 (adeno-associated virus 1) SERCA2a transgene expression in human HF patients, is relevant because nearly half of the patients had DM. CUPID1 enrolled 39 patients with HF and was a phase1/2 trial using percutaneous intracoronary infusion of AAV1/SERCA2a. 10 Improvements in clinical and cardiac measurements occurred in the high dose AAV1/SERCA2a group. A subsequent larger phase2b CUPID2 trial, however, failed to demonstrate a reduction in recurrent HF hospitalization. A specific cause for the different results of CUPID1 versus CUPID2 is difficult to identify, but the patient numbers in CUPID1 were small, and the improvements may have been the play of chance despite positive statistics. Alternatively, a low level of cardiac AAV1/ SERCA2a expression occurred in CUPID2 and is, therefore, a potential contributor to the failure to demonstrate benefit. The preparation of AAV1/SERCA2a for CUPID1 versus CUPID2 was different and may have contributed to the discrepant results. 10 In contrast to humans, successful peripheral intravenous administration of AAV9. Forty-five transgenes occurs in rodents, with transgene expression in a high percent of cardiomyocytes. For humans, the AAV transgene approach needs further development but has been curtailed by limited funding. 11 HF is a multifactorial condition, and focusing only on SERCA2a rectification may be insufficient.
Mitochondrial Ca 2+ Handling in Diabetic Cardiomyocytes
MCUC (mitochondrial calcium uniporter complex)-based cardiomyocyte mitochondrial Ca 2+ import, as well as mitochondrial Ca 2+ export by the mitochondrial sodium calcium lithium exchanger, and the influence which the free mitochondrial matrix calcium level ([Ca 2+ ] m ) has on mitochondrial energetic function have been reviewed. 12 The MCUC is a highly selective channel that moves Ca 2+ ions across the mitochondrial inner membrane driven by the mitochondrial membrane potential (Δψ m ) . Four MCU homodimers form the Ca 2+ channel pore. EMRE (essential MCU regulator) is a 7 kDa protein which is essential for MCUC Ca 2+ conductance. The Ca 2+ -sensing proteins MICU1 (mitochondrial calcium uptake 1) and MICU2 form dimers and interact electrostatically with EMRE and directly with MCU. Mitochondrial Ca 2+ import and export determine [Ca 2+ ] m which stimulates oxidative phosphorylation by enhancing the activity of complex I, III, IV, and the V max of complex V, leading to increased ATP formation. The PDC (pyruvate dehydrogenase complex), mediating glucose oxidation, is also activated by [Ca 2+ ] m . With increased glucose oxidation, the oxidation of FA decreases, diminishing oxygen consumption for contractile work, making it more energetically efficient.
In T1D hearts, MCU and EMRE are significantly decreased. Decreased transcriptional expression of the MCU gene is mediated by high glucose exposure. 
Summary
HF due to DC was described over 40 years ago, and in the past 3 decades, new knowledge, largely derived from diabetic animal models, has accumulated. These results have shown that decreased function of diabetic cardiomyocytes is a significant contributor to the development of HF. Decreased cardiomyocyte function of the diabetic heart was, however, not included amongst the contributing factors in the original description. 2 Currently, only a small number of studies from patients with DM exploring myocardial function and the molecular mechanisms mediating it have been reported. If one accepts guidance from T1D and T2D animal models, improving cytosolic Ca 2+ and especially mitochondrial Ca 2+ handling of the human diabetic heart are appropriate targets for future therapeutic interventions.
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